课题基金 / 基金详情

Immersive Team-Based Design in Undergraduate Bioengineering Education

Immersive Team-Based Design in Undergraduate Bioengineering Education
本科生物工程教育中的沉浸式团队设计
批准号:
8244404
负责人:
Amy Elizabeth Herr
金额:
$4.32万
依托单位国家:
美国
项目类别:
财政年份:
2011
资助国家:
美国
项目状态:
已结题
起止时间:
2011-04-01 至 2016-03-31

项目摘要

项目成果

Amy Elizabeth Herr的其他基金

相似基金

相关文献

中文摘要
翻译
描述(由申请人提供):加州大学伯克利分校的生物工程系(BioE)已经确定了一个迫切的社会需要教育伯克利的生物工程师在医疗技术的挑战性领域的下一个干部。由于最近的课程和计划的发展,时机是正确的,对加州大学伯克利分校的毕业生物工程师,更广泛地说,美国的一个实质性的和可扩展的积极培训影响。我们建议加强和显着扩展现有的(新的)核心项目为基础的课程,并从事我们的毕业生在课程前“临床沉浸”和课程后“翻译沉浸”期间。建议结合教学和体验式培训将提供一个全面的介绍,在转化医学的竞技场创新-与实践临床工作补充理论知识的目的。我们利用现有的基于项目的课程作为教育计划的核心,该教育计划将通过新提出的(a)课程前(夏季)“临床沉浸”时期使高级生物工程本科生接触转化医学,以确定加州大学旧金山分校弗朗西斯科医学中心未满足的临床需求,(B)在与UCSF临床“客户”的扩展高级设计项目课程期间增强团队项目机会和导师,以及(c)项目后的“转化沉浸”学期,学生利用他们新获得的工程设计技能和对转化挑战的理解,与一系列临床专家和行业领导者合作,了解工程在医学中的作用。通过R25,我们将通过三个具体目标培养本科生理解,参与和领导医疗技术创新:1)挑战我们的学生识别和定义生物医学问题,以实现有意义的生物工程解决方案,2)使用开放式生物医学问题引入工程设计方法,同时培养跨学科和团队创新的环境,促进和鼓励,3)提供一个受保护的培训期,在此期间,我们的学生通过发明,原型设计和新技术,诊断和治疗的测试,满足与临床和商业领袖协商的真正临床需求,围绕开放的生物医学问题进行创新。 公共卫生相关性:增加具有转化医学教学和经验培训的新生物工程师的数量将增加和改善以需求为中心的医学创新。工程专业的学生在转化医学培训中面临挑战,即获得临床经验和指导。在与UCSF和周围的医疗计划合作,加州大学伯克利分校的建议R25将在生物工程学士学位的最后一年引入一个“翻译培训”管道计划。课程。
英文摘要
DESCRIPTION (provided by applicant): UC Berkeley's Department of Bioengineering (BioE) has identified a compelling societal need to educate the next cadre of Berkeley's bioengineers in the challenging area of medical technology. Owing to recent course and program development, the timing is right for a substantial and scalable positive training impact on UC Berkeley's graduating bioengineers and, more broadly, the US. We propose to enhance and significantly extend an existing (new) core project-based course and engage our graduating seniors in both a pre-course 'Clinical Immersion' and post-course 'Translational Immersion' periods. The proposed combined didactic and experiential training will provide a comprehensive introduction to innovating in the arena of translational medicine -- with the aim of supplementing theoretical knowledge with hands-on clincial work. We leverage an existing project-based course as the kernel for a educational program that will expose senior bioengineering undergraduates to translational medicine through newly proposed (a) pre-course (summer) 'Clinical Immersion' periods to identify unmet clinical needs at UC San Francisco Medical Centers, (b) enhanced team-project opportunities and mentors during an expanded senior design project course with UCSF clinical 'clients', and (c) a post-project 'Translational Immersion' semester in which students use their newly acquired engineering design skills & appreciation for translational challenges to engage a spectrum of clinical experts & industry leaders to understand the role of engineering in medicine. Through the R25, we will train undergraduates to understand, engage in, and lead medical technology innovation through three Specific Aims: 1) Challenge our students to identify and define biomedical problems to achieve meaningful bioengineering solutions, 2) Introduce engineering design approaches using open-ended biomedical problems, while fostering an environment in which interdisciplinary and team-based innovation are promoted & encouraged, 3) Provide a protected training period during which our students innovate around open biomedical problems through invention, prototyping, and testing of new technologies, diagnostics, and therapies which meet a true clinical need in consultation with clinical and business leaders. PUBLIC HEALTH RELEVANCE: Increasing the number of new bioengineers with didactic & experiential training in translational medicine will increase and improve needs-centered innovation in medicine. Engineering students face challenges in translational medicine training, namely in gaining clinical experience and mentoring. In collaboration with UCSF and surrounding medical programs, UC Berkeley's proposed R25 will introduce a 'translational training' pipeline program in the culminating year of the BioE B.S. curriculum.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
MULTIPLEXED ISOFORM QUANTIFICATION IN HER2-POSITIVE BREAST CANCER
  • 批准号:
    10362550
  • 项目类别:
  • 资助金额:
    $34.53万
  • 财政年份:
    2021
  • 负责人:
    Amy Elizabeth Herr
  • 依托单位:
MULTIPLEXED ISOFORM QUANTIFICATION IN HER2-POSITIVE BREAST CANCER
  • 批准号:
    10583566
  • 项目类别:
  • 资助金额:
    $35.05万
  • 财政年份:
    2021
  • 负责人:
    Amy Elizabeth Herr
  • 依托单位:
Advanced Cancer Classification via Single-Cell Electrophoretic Cytopathology
  • 批准号:
    9482979
  • 项目类别:
  • 资助金额:
    $145.39万
  • 财政年份:
    2017
  • 负责人:
    Amy Elizabeth Herr
  • 依托单位:
Multiplexed isoform quantification in HER2-positive breast cancer
  • 批准号:
    9390766
  • 项目类别:
  • 资助金额:
    $34.78万
  • 财政年份:
    2015
  • 负责人:
    Amy Elizabeth Herr
  • 依托单位:
国内基金
海外基金
层出镰刀菌氮代谢调控因子AreA 介导伏马菌素 FB1 生物合成的作用机理
  • 批准号:
    2021JJ40433
  • 项目类别:
    省市级项目
  • 资助金额:
    --
  • 批准年份:
    2021
  • 负责人:
    孙磊
  • 依托单位:
寄主诱导梢腐病菌AreA和CYP51基因沉默增强甘蔗抗病性机制解析
  • 批准号:
    32001603
  • 项目类别:
    青年科学基金项目
  • 资助金额:
    24.0万元
  • 批准年份:
    2020
  • 负责人:
    段真珍
  • 依托单位:
AREA国际经济模型的移植.改进和应用
  • 批准号:
    18870435
  • 项目类别:
    面上项目
  • 资助金额:
    2.0万元
  • 批准年份:
    1988
  • 负责人:
    史树中
  • 依托单位: